Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C32H29N5O2
CAS Number:
Molecular Weight:
515.60
UNSPSC Code:
12352200
NACRES:
NA.77
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
, light orange to dark orange-red
solubility
DMSO: 10 mg/mL, clear (warmed)
storage temp.
−20°C
SMILES string
N1C(=O)C(=C(C1=O)c6c7c([n](c6)C)cccc7)c2c3c([n](c2)C4CCN(CC4)Cc5ncccc5)cccc3
InChI
1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)
InChI key
AXRCEOKUDYDWLF-UHFFFAOYSA-N
Application
Enzastaurin has been used in splicing analysis to study its effects on splicing of a mutated exon.
Biochem/physiol Actions
Enzastaurin is a potent and PKCβ preferring inhibitor. Also, Enzastaurin inhibits AKT and GSK3β. Enzastaurin acts as anti-angiogenic and antineoplastic agent.
Enzastaurin is a potent and PKCβ proffering inhibitor.
It is an orally administered drug. It can induce apoptosis, inhibit angiogenesis and proliferation of cells. Enzastaurin can be used for the treatment of haematological cancers.
Features and Benefits
This compound is featured on the GSK-3, PKB/Akt and PKC pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 4
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Enzastaurin: A lesson in drug development.
Bourhill T
Critical Reviews in Oncology/Hematology (2017)
Staurosporine allows dystrophin expression by skipping of nonsense-encoding exon
Atsushi N
Brain & Development (2016)
Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma.
Fabro, et al.
Frontiers in Oncology, 12, 1012236-1012236 (2022)
